EVM
CDAK

Eaton Vance Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Eaton Vance Management’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$22K – 2855
2021
Q4 		$22K Hold
2,000
– – ﹤0.01% 2377
2021
Q3 		$0 Hold
2,000
– – ﹤0.01% 2828
2021
Q2 		$37K Buy
+2,000
New +$38.4K ﹤0.01% 2258

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Eaton Vance Management's CDAK Position: Q1 2022 in Review

Eaton Vance Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q1 2022, closing a stake of 2,000 shares — an estimated $22K sold.

Eaton Vance Management first reported a position in CDAK in Q2 2021 and held it in 3 quarters. The position peaked at $37K in Q2 2021. 62 funds tracked by Wall St. Rank hold CDAK as of Q1 2022.

  • Eaton Vance Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 2,000 Codiak BioSciences, Inc. Common Stock shares in Q1 2022, an estimated $22K.
  • Eaton Vance Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Codiak BioSciences, Inc. Common Stock position peaked at $37K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.